{"id":807693,"date":"2025-02-03T07:34:00","date_gmt":"2025-02-03T12:34:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"},"modified":"2025-02-03T07:34:00","modified_gmt":"2025-02-03T12:34:00","slug":"dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","title":{"rendered":"Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">WALTHAM, Mass., Feb.  03, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RrR140K_Z0Dg1bUgXAQqcypqj3JCGxfE8KZnPl3TESBsd7wQwR_UFSenuGRp0JqOEOhL-PMN9I2lXH4KdNmzQlzlxKeNoJBqx-Dt141Be3I=\" rel=\"nofollow\" target=\"_blank\">Dyne Therapeutics, Inc<\/a>. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 4:00 p.m. ET.<\/p>\n<p>A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w4kbeR1E32x-bODNbdBF3LNmgK-AZTUB-SU5kFp0TkgZGiIeouFC7LEmLreV4vjuj4Sh8mGAjvQyh2N4dz-8gsbuHNml9hhAzYq-t9KM6P9Gv4d6EfUiWL33aQP9PXKkZR9HtG_xgxfD7OEfpfIxrI7jUisHh04exUPYNgHQRx5S3VAC1j1RK7CASZPoJWtxFIvaRTBUyNjXatV7o9Qeh6_2nqKBN_BFIf596mgTxKA-EYQEJogRRE_kgdqmzLFB2LUC6bK9XJzh69Xcj_tKo3ygXH6GYyVqcik3AqBI-t8UG8hckjrQsN4GQR4ukvCAWtgZpArn87KqmVHM4oHD4A5IlVIlebZZ73DM8PsnfR0N0kzVZ9IRLzXnrCfLklkhqmKN9HLcQPaE3H6pApP3K7FtdDWFGR-DLFX2yt60f3MK1xmq6gFvGeOGJ_2mk23sgzIrvIHUgLr-KGCCrVmOpJzVARMFRQ2wldDcN02trWdDrZixSggS4XjfQw4vCS5zW3kB-NTv96jmIVjNsULIWOYpeLYkqUPpLY9aCxMVFMxmze2ermxf80JA-W5jnUpyD8MFMnj4AXiwCEFHZp4_vJD9zIsOqcrS3C0SDkzUyR-8-CJfbTQ-rSHv9dFYxXq-xK24Y0ATlzE1uHKeFLRaAaEhbt8kvhKwKNbDtOz2SHDhtsBiW-aCgS88xvuTl2mgFlLp1OoluKXNZruJD1KulsalLsKNIt-zTF284T7oNlnDY6sj9ym1Rl2qxxLU9LChpFvFYkZNhNX5c5mdhjftxMrdoJaC2MppfJVijKpiYjCqCdVHeMsVKusOq3huhmJEh22RpYyJWGm7JSdok2gMBubiaANSbN-5QCWlhVuT1Zg=\" rel=\"nofollow\" target=\"_blank\">https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations<\/a>\u00a0and a replay will be accessible for 90 days following the presentation.<\/p>\n<p>\n        <strong>About Dyne Therapeutics<\/strong>\n      <\/p>\n<p>Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE\u2122 platform, Dyne is developing targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system (CNS). Dyne has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD) and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w4kbeR1E32x-bODNbdBF3NznWcJyA9Ku-rHV0WioUwEygaDrz0WdKqIRwU1qBBTXUbAZWw5r6RYr7UENz0ipGsq1k9d6ij59PbUkeKrHncU=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.dyne-tx.com\/<\/a>, and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E793U8uacouaaNoDUulPG5eq8La46IaMZrz0yxg0pDWTcvqQJNFpTP2rws7-9Fnnz6_RaiZSd1_dl1ZHhr3OJw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZJkPZl8KoFO8UmgOySKOCr3YdZeWcebwO0LZCTJjvSnDFY7Pfpgd7vfErV9SBTVmN6tAbAhFtcRyjGC3HvTOPB5Svo9tmopD8sLHOb82Zx4=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VYKv47qYHQsLg_hOwFfyHmpCOsh1ZXOvhMMduGAV5RPDVPtNAgYdYpoiuze77tlAU-HcMsZlIz0aFExE7ZyP9kbIXnUoF69Drsk-pHKDr2M=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.\u00a0<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Mia Tobias<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vEDxCzgq0NDu-JMjWPZhS-kLh2Dsfw6bq1jW_pyLi9RD5VZ1MumfBpQ7q02zQ-BaYbFalAlN-OJmNz2jfqfsJgOARGpZfANF0OOfoOAhtO_MIm_yH55vBFPddIYNQe-JR2Q43rH3bYeeJx9QZWoxFOePr0jS3A90Ye8uHdanj9Gd3rL7CZW2yaY45xZCNYNjlwCIMeKo1jzc5TRd_q6car0lP6nDptfowYbldyElKgI=\" rel=\"nofollow\" target=\"_blank\">ir@dyne-tx.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Stacy Nartker<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8bODvpCIyXmkZlaEjxF6WpjjbFBDo-VD44I6I4ipgItVMsJwysUX_TYX9Eo8YRcFcfyYQf6h-C5yd3C0_6Rce2W_5bF-THFKl2645I1QwuLVvHYyqdNDy-CD-cu8l_x5w8KjipNhpN1qyuoBImyYdHEpHHsS-ArhNQIQUgvihJbKmaG0V8xlvlyqqBupyfNV8RetIxayioHCwQSbHAV7aYbQZJlX_C5rWDlWuzvaJFMoMKqxys843EsCJbaZbOX5JpnpeUzTIUV91ms6uis20A==\" rel=\"nofollow\" target=\"_blank\">snartker@dyne-tx.com<\/a><br \/>781-317-1938<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTQyOSM2NzMwNjQ5IzIyMDA4OTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDRmM2I5YzctODY2Ni00NjUxLWEyMTctOTFlMzk0OGUzZjU2LTEyMTI0NDU=\/tiny\/Dyne-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 4:00 p.m. ET. A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations\u00a0and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE\u2122 platform, Dyne is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-807693","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 4:00 p.m. ET. A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations\u00a0and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE\u2122 platform, Dyne is &hellip; Continue reading &quot;Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-03T12:34:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTQyOSM2NzMwNjQ5IzIyMDA4OTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference\",\"datePublished\":\"2025-02-03T12:34:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\"},\"wordCount\":219,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MTQyOSM2NzMwNjQ5IzIyMDA4OTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\",\"name\":\"Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MTQyOSM2NzMwNjQ5IzIyMDA4OTI=\",\"datePublished\":\"2025-02-03T12:34:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MTQyOSM2NzMwNjQ5IzIyMDA4OTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1MTQyOSM2NzMwNjQ5IzIyMDA4OTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","og_locale":"en_US","og_type":"article","og_title":"Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk","og_description":"WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) &#8212; Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage neuromuscular disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present during a virtual fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 4:00 p.m. ET. A live webcast will be available in the Investors &amp; Media section of Dyne\u2019s website at\u00a0https:\/\/investors.dyne-tx.com\/news-and-events\/events-and-presentations\u00a0and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics is focused on discovering and advancing innovative life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE\u2122 platform, Dyne is &hellip; Continue reading \"Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-03T12:34:00+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTQyOSM2NzMwNjQ5IzIyMDA4OTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference","datePublished":"2025-02-03T12:34:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"},"wordCount":219,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTQyOSM2NzMwNjQ5IzIyMDA4OTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/","name":"Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTQyOSM2NzMwNjQ5IzIyMDA4OTI=","datePublished":"2025-02-03T12:34:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTQyOSM2NzMwNjQ5IzIyMDA4OTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1MTQyOSM2NzMwNjQ5IzIyMDA4OTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dyne-therapeutics-to-present-at-oppenheimer-35th-annual-healthcare-life-sciences-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/807693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=807693"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/807693\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=807693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=807693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=807693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}